Oxford Biomedica plc Preliminary results for the year ended 31 December 2019

    NEXT STORY
    Allogene Therapeutics Reports First Quarter 2020 Financial Results
    PREV STORY
    ProMIS Neurosciences develops novel antagonists for RACK1, a protein involved in numerous neurodegenerative diseases, including ALS
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Ascendis Pharma A/S Announces Presentation of Preclinical Data for TransCon IL-2 β/γ at AACR Virtual Annual Meeting 2020

    author_avatar
    NASDAQ Market News

    Coherus BioSciences Receives Complete Response Letter from FDA for its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)

    REDWOOD CITY, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today ...

    author_avatar
    NASDAQ Market News

    NewLink Genetics Provides Operational & Clinical Update, Reports Fourth Quarter, Year-End 2016 Financial Results

    AMES, Iowa, Feb. 28, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical ...

    author_avatar
    NASDAQ Market News